ketanserin has been researched along with Liver Cirrhosis in 6 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We measured the hemodynamic effects of intravenous vasopressin, ketanserin (a 5-hydroxytryptamine-2 receptor blocker), and vasopressin plus ketanserin in 33 patients with hepatitis B-related cirrhosis." | 9.07 | Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis b-related cirrhosis. ( Hsia, HC; Lai, KH; Lee, FY; Lee, SD; Lin, HC; Lin, WJ; Lo, KJ; Tsai, YT; Wang, SS, 1992) |
| "The effect of ketanserin on inflammation, liver fibrosis, and microviscosity of the plasma and mitochondrial membranes of hepatocytes was studied on young (3 months) and old (9 months) male Wistar rats with experimental liver cirrhosis." | 8.12 | Age-Related Features of Ketanserin Effects in Experimental Liver Cirrhosis. ( Afanas'ev, SA; Dygai, АМ; Ermakova, NN; Kogai, LV; Pakhomova, AV; Pan, ES; Pershina, ОV; Putrova, ОD; Rebrova, ТY; Sandrikina, LА; Skurikhin, ЕG; Zhukova, МА, 2022) |
| "Affinities and densities of binding sites for the 5HT1A receptor ligand [3H]8-hydroxy(di-n-propylamino)tetralin ([3H]8-OH-DPAT) and the 5HT2 receptor ligand [3H]ketanserin were measured using a rapid filtration assay in crude membrane preparations from frontal cortex and hippocampus of nine cirrhotic patients who died in hepatic encephalopathy and from an equal number of age-matched subjects free from hepatic, neurological or psychiatric disorders." | 7.69 | Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. ( Butterworth, RF; Rao, VL, 1994) |
| "We measured the hemodynamic effects of intravenous vasopressin, ketanserin (a 5-hydroxytryptamine-2 receptor blocker), and vasopressin plus ketanserin in 33 patients with hepatitis B-related cirrhosis." | 5.07 | Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis b-related cirrhosis. ( Hsia, HC; Lai, KH; Lee, FY; Lee, SD; Lin, HC; Lin, WJ; Lo, KJ; Tsai, YT; Wang, SS, 1992) |
| "The effect of ketanserin on inflammation, liver fibrosis, and microviscosity of the plasma and mitochondrial membranes of hepatocytes was studied on young (3 months) and old (9 months) male Wistar rats with experimental liver cirrhosis." | 4.12 | Age-Related Features of Ketanserin Effects in Experimental Liver Cirrhosis. ( Afanas'ev, SA; Dygai, АМ; Ermakova, NN; Kogai, LV; Pakhomova, AV; Pan, ES; Pershina, ОV; Putrova, ОD; Rebrova, ТY; Sandrikina, LА; Skurikhin, ЕG; Zhukova, МА, 2022) |
| "Affinities and densities of binding sites for the 5HT1A receptor ligand [3H]8-hydroxy(di-n-propylamino)tetralin ([3H]8-OH-DPAT) and the 5HT2 receptor ligand [3H]ketanserin were measured using a rapid filtration assay in crude membrane preparations from frontal cortex and hippocampus of nine cirrhotic patients who died in hepatic encephalopathy and from an equal number of age-matched subjects free from hepatic, neurological or psychiatric disorders." | 3.69 | Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. ( Butterworth, RF; Rao, VL, 1994) |
| " Pharmacokinetic parameters were calculated using noncompartmental analysis based on a statistical moment theory." | 2.67 | Pharmacokinetics of ketanserin in patients with cirrhosis. ( Benhamou, JP; Berthelot, P; Fraitag, B; Gaudin, C; Hadengue, A; Lebrec, D; Levron, JC, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, ES | 1 |
| Pakhomova, AV | 1 |
| Ermakova, NN | 1 |
| Afanas'ev, SA | 1 |
| Rebrova, ТY | 1 |
| Zhukova, МА | 1 |
| Sandrikina, LА | 1 |
| Putrova, ОD | 1 |
| Kogai, LV | 1 |
| Pershina, ОV | 1 |
| Dygai, АМ | 1 |
| Skurikhin, ЕG | 1 |
| Oldenburger, A | 1 |
| Birk, G | 1 |
| Schlepütz, M | 1 |
| Broermann, A | 1 |
| Stierstorfer, B | 1 |
| Pullen, SS | 1 |
| Rippmann, JF | 1 |
| Li, T | 1 |
| Weng, SG | 1 |
| Leng, XS | 1 |
| Peng, JR | 1 |
| Wei, YH | 1 |
| Mou, DC | 1 |
| Wang, WX | 1 |
| Rao, VL | 1 |
| Butterworth, RF | 1 |
| Lee, FY | 1 |
| Tsai, YT | 1 |
| Lin, HC | 1 |
| Lee, SD | 1 |
| Hsia, HC | 1 |
| Lin, WJ | 1 |
| Wang, SS | 1 |
| Lai, KH | 1 |
| Lo, KJ | 1 |
| Lebrec, D | 1 |
| Hadengue, A | 1 |
| Gaudin, C | 1 |
| Levron, JC | 1 |
| Fraitag, B | 1 |
| Berthelot, P | 1 |
| Benhamou, JP | 1 |
2 trials available for ketanserin and Liver Cirrhosis
| Article | Year |
|---|---|
Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis b-related cirrhosis.
Topics: Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Rate; Hemodynamics; H | 1992 |
Pharmacokinetics of ketanserin in patients with cirrhosis.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Female; Humans; Injections, Intravenous; | 1990 |
4 other studies available for ketanserin and Liver Cirrhosis
| Article | Year |
|---|---|
Age-Related Features of Ketanserin Effects in Experimental Liver Cirrhosis.
Topics: Animals; Hepatocytes; Inflammation; Ketanserin; Liver; Liver Cirrhosis; Liver Cirrhosis, Experimenta | 2022 |
Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices.
Topics: Adenosine Triphosphate; Animals; Blood Vessels; Carbon Tetrachloride; Endothelin-1; Ketanserin; Live | 2021 |
Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells.
Topics: Animals; Blotting, Western; Cells, Cultured; Gene Expression; Ketanserin; Liver; Liver Cirrhosis; Ma | 2006 |
Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Autopsy; Binding Sites; Brain; Hepatic Encephalopathy; Human | 1994 |